JP3185984U - Sweet potato protein composite particle structure with enhanced satiety, blood glucose level and blood fat regulation function - Google Patents
Sweet potato protein composite particle structure with enhanced satiety, blood glucose level and blood fat regulation function Download PDFInfo
- Publication number
- JP3185984U JP3185984U JP2013003766U JP2013003766U JP3185984U JP 3185984 U JP3185984 U JP 3185984U JP 2013003766 U JP2013003766 U JP 2013003766U JP 2013003766 U JP2013003766 U JP 2013003766U JP 3185984 U JP3185984 U JP 3185984U
- Authority
- JP
- Japan
- Prior art keywords
- sweet potato
- particle structure
- protein
- composite particle
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 244000017020 Ipomoea batatas Species 0.000 title claims abstract description 108
- 235000002678 Ipomoea batatas Nutrition 0.000 title claims abstract description 108
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 92
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 92
- 239000008280 blood Substances 0.000 title claims abstract description 74
- 210000004369 blood Anatomy 0.000 title claims abstract description 74
- 239000011246 composite particle Substances 0.000 title claims abstract description 54
- 235000019627 satiety Nutrition 0.000 title claims abstract description 34
- 230000036186 satiety Effects 0.000 title claims abstract description 34
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 17
- 239000008103 glucose Substances 0.000 title claims abstract description 17
- 230000033228 biological regulation Effects 0.000 title claims description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- 239000010410 layer Substances 0.000 claims abstract description 24
- 235000000346 sugar Nutrition 0.000 claims abstract description 22
- 230000001105 regulatory effect Effects 0.000 claims abstract description 21
- 239000011241 protective layer Substances 0.000 claims abstract description 15
- 239000002753 trypsin inhibitor Substances 0.000 claims abstract description 12
- 101710162629 Trypsin inhibitor Proteins 0.000 claims abstract description 11
- 229940122618 Trypsin inhibitor Drugs 0.000 claims abstract description 11
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 8
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 8
- 230000004060 metabolic process Effects 0.000 claims abstract description 6
- 239000000284 extract Substances 0.000 claims description 13
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 9
- 244000183685 Citrus aurantium Species 0.000 claims description 8
- 235000007716 Citrus aurantium Nutrition 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 6
- 229940046374 chromium picolinate Drugs 0.000 claims description 6
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 claims description 6
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 claims description 6
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 claims description 6
- 229960003966 nicotinamide Drugs 0.000 claims description 6
- 235000005152 nicotinamide Nutrition 0.000 claims description 6
- 239000011570 nicotinamide Substances 0.000 claims description 6
- 235000019895 oat fiber Nutrition 0.000 claims description 6
- 239000006041 probiotic Substances 0.000 claims description 6
- 235000018291 probiotics Nutrition 0.000 claims description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 5
- 229930003471 Vitamin B2 Natural products 0.000 claims description 5
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 5
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 5
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 5
- 235000020733 paullinia cupana extract Nutrition 0.000 claims description 5
- 229960002477 riboflavin Drugs 0.000 claims description 5
- 235000019164 vitamin B2 Nutrition 0.000 claims description 5
- 239000011716 vitamin B2 Substances 0.000 claims description 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 238000013270 controlled release Methods 0.000 claims description 3
- 229960004799 tryptophan Drugs 0.000 claims description 3
- 229960004441 tyrosine Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 238000010276 construction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 235000018102 proteins Nutrition 0.000 description 63
- 235000019197 fats Nutrition 0.000 description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 239000003826 tablet Substances 0.000 description 15
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 11
- 239000007888 film coating Substances 0.000 description 11
- 238000009501 film coating Methods 0.000 description 11
- 235000019789 appetite Nutrition 0.000 description 10
- 230000036528 appetite Effects 0.000 description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- 235000013325 dietary fiber Nutrition 0.000 description 9
- 239000001913 cellulose Substances 0.000 description 8
- 229920002678 cellulose Polymers 0.000 description 8
- 235000010980 cellulose Nutrition 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 230000037149 energy metabolism Effects 0.000 description 6
- 235000019525 fullness Nutrition 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 102100025841 Cholecystokinin Human genes 0.000 description 4
- 101800001982 Cholecystokinin Proteins 0.000 description 4
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 4
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229940107137 cholecystokinin Drugs 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- BQMPVGMHZKZPBH-BYZBDTJCSA-N (3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O.C[N+](C)(C)C[C@H](O)CC([O-])=O BQMPVGMHZKZPBH-BYZBDTJCSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108010089335 Cholecystokinin A Receptor Proteins 0.000 description 2
- 102100034927 Cholecystokinin receptor type A Human genes 0.000 description 2
- KCXZNSGUUQJJTR-UHFFFAOYSA-N Di-n-hexyl phthalate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCC KCXZNSGUUQJJTR-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007937 eating Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 235000015816 nutrient absorption Nutrition 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000027756 respiratory electron transport chain Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NVEKVXJOGMAPCY-UHFFFAOYSA-N 2-(3-hydroxypropoxycarbonyl)benzoic acid Chemical compound OCCCOC(=O)C1=CC=CC=C1C(O)=O NVEKVXJOGMAPCY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 241000207782 Convolvulaceae Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000004181 Eucalyptus cladocalyx Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 235000000556 Paullinia cupana Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000019218 bitter orange extract Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- CRVGKGJPQYZRPT-UHFFFAOYSA-N diethylamino acetate Chemical compound CCN(CC)OC(C)=O CRVGKGJPQYZRPT-UHFFFAOYSA-N 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- -1 penetrant Substances 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 210000000636 white adipocyte Anatomy 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
【課題】満腹感を高め、血糖値及び血中脂肪調節機能を備えたサツマイモのタンパク質複合粒子構造を提供する。
【解決手段】サツマイモのタンパク質複合粒子構造1は、サツマイモのタンパク質を含む深部コア30と、サツマイモのタンパク質を含む深部コアの外層を包覆する有効成分層20と、該有効成分層の外層を包覆する保護層10とを含む。そのうち、サツマイモのタンパク質はトリプシンインヒビター(Trypsin inhibitor)と糖タンパク質(glycoprotein)を含み、満腹感を高め、血糖値及び血中脂肪を調節し、代謝を促進するさまざまな効果を達成する。
【選択図】図1The present invention provides a protein composite particle structure of sweet potato with enhanced satiety and blood glucose level and blood fat regulating functions.
A sweet potato protein composite particle structure 1 includes a deep core 30 containing a sweet potato protein, an active ingredient layer 20 covering an outer layer of the deep core containing a sweet potato protein, and an outer layer of the active ingredient layer. And a protective layer 10 to be covered. Among them, the sweet potato protein contains trypsin inhibitor and glycoprotein, which enhances satiety, regulates blood sugar and blood fat, and achieves various effects of promoting metabolism.
[Selection] Figure 1
Description
本考案はサツマイモのタンパク質複合粒子構造に関し、満腹感を高め、血糖値及び血中脂肪調節機能を備えたサツマイモのタンパク質複合粒子構造に係る。 The present invention relates to a protein composite particle structure of sweet potato, and relates to a protein composite particle structure of sweet potato that increases satiety and has blood glucose level and blood fat regulating functions.
健康な体を持つことは現代人が心底熱望する目標である。肥満は不健康な身体となる主原因の一つである。肥満は心血管疾患、高血圧、糖尿病、脂肪肝、内分泌失調やいくつかの癌の原因となりうる。 Having a healthy body is a goal that modern people are eagerly aspiring to. Obesity is one of the main causes of unhealthy bodies. Obesity can cause cardiovascular disease, hypertension, diabetes, fatty liver, endocrine disorders, and some cancers.
いかに少量或いは低カロリーの食物を摂取後に満腹感を感じさせ、食欲を満足させるとともに、ダイエット効果を達成するかが現代人の最も関心のある話題である。満腹感を感じさせる食べ物は体積及び重量と関係があり、体積が大きくなるほど食べ物は満腹感を感じさせる。例えば、食物の繊維素、タンパク質含有量、及び水分と量の多さも比較的満腹感が得られる。 The most interesting topic of modern people is how to make them feel full after eating a small or low-calorie food, satisfy their appetite, and achieve a diet effect. Food that makes you feel full is related to volume and weight, and the larger the volume, the more the food feels full. For example, dietary fiber, protein content, and a high amount of water and amount can also provide a relatively full feeling.
よって、市場では満腹感の得られる食物及び飲料は主に、食物繊維を主としている。それは、人体に消化分解されない或いは難消化の多糖類及びリグニンであり、消化器官で水分を吸収する作用を備え、腸管と胃内の食物の体積を増加させ、満腹感を得られる。例えば、寒天、コンニャク、チコリの繊維等によって作られた食物や飲み物である。これらの食物繊維は満腹感を得られる他、胃腸の動きを促進し、同時に血液中のコレステロール、トリグリセリドを低下させ、肥満を予防する。しかし、長期的に腹部にガスが溜まり、消化不良を起こしている人が大量の食物繊維を摂取すると、却って胃からの排出を遅らせ、ミネラル物質の吸収を抑える副作用が引き起こされる。また、食物繊維は口当たりがよくなく、飲料は携帯が不便で開封後はただちに消費しなければならず、保存上にも難がある。 Thus, foods and beverages that provide a feeling of fullness in the market are mainly dietary fiber. It is a polysaccharide and lignin that cannot be digested and decomposed by the human body, has a function of absorbing water in the digestive tract, increases the volume of food in the intestinal tract and stomach, and provides a feeling of fullness. For example, foods and drinks made from agar, konjac, chicory fiber, etc. In addition to providing a feeling of fullness, these dietary fibers promote gastrointestinal movement, and at the same time, lower cholesterol and triglycerides in the blood to prevent obesity. However, if a person who is suffering from indigestion ingests a large amount of dietary fiber in the abdomen for a long time, a side effect of delaying the discharge from the stomach and suppressing the absorption of mineral substances is caused. In addition, dietary fiber is not palatable, and beverages are inconvenient to carry and must be consumed immediately after opening, which makes storage difficult.
現在、一般の食物繊維飲料の携帯上及び保存上の困難と口当たりの悪い欠点を改善することが非常に期待されるところであり、これにより一般使用者は直接的且つ便利な方法で満腹感を得る目的を達成し、更に身体の健康に役立つ機能性のあるサプリメントを取得できる。 Currently, it is highly expected to improve the portability and unpleasant shortcomings of common dietary fiber drinks, which gives the general user a feeling of fullness in a direct and convenient way. You can get functional supplements that will help you achieve your goals and help your health.
本考案の一つの目的は、満腹感を高め、血糖値及び血中脂肪調節機能を備えたサツマイモのタンパク質複合粒子構造を提供することにある。それは、サツマイモのタンパク質を含む深部コアと、深部コアの外層を包覆する有効成分層と、該有効成分層の外層を包覆する保護層とを含む。そのうち、サツマイモのタンパク質はトリプシンインヒビター(Trypsin inhibitor)と糖タンパク質(glycoprotein)を含み、それは腸で容易に吸収され、効果的に満腹感を高め、血糖値、血中脂肪を調節し、代謝を促進する。並びに、サツマイモのタンパク質複合粒子構造の粒径は120μmから500μmの範囲内とし、サツマイモのタンパク質を含む深部コアの厚さは30μmから150μmの範囲内とし、有効成分層の厚さは20μmから70μmの範囲内とする。 One object of the present invention is to provide a protein composite particle structure of sweet potato with enhanced satiety and blood glucose level and blood fat regulating functions. It includes a deep core containing a sweet potato protein, an active ingredient layer covering the outer layer of the deep core, and a protective layer covering the outer layer of the active ingredient layer. Among them, sweet potato proteins contain trypsin inhibitors and glycoproteins that are easily absorbed in the intestine, effectively increasing satiety, regulating blood sugar levels, blood fat, and promoting metabolism. To do. In addition, the particle size of the protein composite particle structure of sweet potato is in the range of 120 μm to 500 μm, the thickness of the deep core containing the sweet potato protein is in the range of 30 μm to 150 μm, and the thickness of the active ingredient layer is 20 μm to 70 μm. Within range.
本考案の満腹感を高め、血糖値及び血中脂肪調節機能を備えたサツマイモのタンパク質複合粒子構造において、サツマイモのタンパク質を含む深部コアには オート麦繊維(Oat Cellulose)をさらに添加することで栄養吸収を減少させるのを助け、尚且つ満腹感を促進し、血中脂肪及びコレステロールを低下させる。 In this sweet potato protein composite particle structure with enhanced blood sugar level and blood fat regulation function, the oat fiber (Oat Cellulose) is further added to the deep core containing the sweet potato protein. Helps reduce absorption and promotes satiety and lowers blood fat and cholesterol.
本考案の満腹感を高め、血糖値及び血中脂肪調節機能を備えたサツマイモのタンパク質複合粒子構造において、有効成分層は、ガラナ(Guarana)エキス、ダイダイ(Bitter orange)エキス、L-カルニチン(L-Carnitine)、コエンザイム(Coenzyme)Q10、フコキサンチン(Fucoxanthin)、プロバイオティクス(Probiotics)、ビタミンB6、ビタミンB2、ピコリン酸クロム(chromium picolinate)、トリプトファン(Tryptophan)、チロシン(Tyrosine)、バナバ葉(Banaba leaf)エキス、ナイアシンアミド(Niacinamide)、及びその任意の組み合わせより、少なくとも一種の成分を選択し、組成するグループである。前記有効成分層の成分は満腹感を高め、食欲を抑制し、エネルギー代謝を促進し、血糖値調節を強化し、脂肪分解を加速するのを助ける。 In the protein composite particle structure of sweet potato with enhanced satiety and blood glucose level and blood fat regulating function of the present invention, the active ingredient layer is composed of Guarana extract, Daidai (Bitter orange) extract, L-carnitine (L -Carnitine), Coenzyme Q10, Fucoxanthin, Probiotics, Vitamin B6, Vitamin B2, Chromium picolinate, Tryptophan, Tyrosine, Banaba leaf ( It is a group that selects and composes at least one component from Banaba leaf extract, Niacinamide, and any combination thereof. The ingredients in the active ingredient layer increase satiety, suppress appetite, promote energy metabolism, strengthen blood sugar regulation, and accelerate lipolysis.
本考案の一つの好ましい実施例では、サツマイモのタンパク質複合粒子構造は保健用食品或いは医薬品である。それはカプセルに充填するか錠剤の形態をとる。そのうち、錠剤は二層錠、発砲錠、放出制御錠である。 In one preferred embodiment of the present invention, the protein composite particle structure of sweet potato is a health food or pharmaceutical product. It fills capsules or takes the form of tablets. Among them, tablets are bilayer tablets, foamed tablets, and release-controlled tablets.
本考案の一つの好ましい実施例では、サツマイモのタンパク質複合粒子構造は袋詰めパックに充填するか飲料の形態をとる。 In one preferred embodiment of the invention, the sweet potato protein composite particle structure is filled into a bag or in the form of a beverage.
本考案は、一般の食物繊維の満腹感を提供する他、同時に食欲を抑制し、血糖値、血中脂肪を調節し、脂肪分散を加速し、代謝を促進するさまざまな効果を備える。本考案の提供するサツマイモのタンパク質複合粒子構造は、同時に身体の健康に役立つ機能性サプリメントでもあり、一般の食物繊維の飲料の携帯上及び使用上の困難を改善し、安定性に優れた長所を持つ。これにより、一般使用者はサツマイモ中の豊富な栄養を直接的に、便利に取得することができる。本考案のサツマイモのタンパク質複合粒子構造は、満腹感を高め、血糖値及び血中脂肪を調節し、代謝を促進するさまざまな効果を備える。該複合粒子構造にはサツマイモのタンパク質の活性成分を含み、該活性成分の保存期限を延長することができる。 In addition to providing a feeling of fullness of general dietary fiber, the present invention has various effects of simultaneously suppressing appetite, regulating blood sugar level and blood fat, accelerating fat dispersion, and promoting metabolism. The protein composite particle structure of sweet potato provided by the present invention is also a functional supplement useful for physical health, which improves the difficulty of carrying and using common dietary fiber drinks, and has the advantages of excellent stability. Have. Thereby, a general user can acquire abundant nutrition in sweet potato directly and conveniently. The protein composite particle structure of sweet potato of the present invention has various effects of enhancing satiety, regulating blood sugar level and blood fat, and promoting metabolism. The composite particle structure includes an active ingredient of a protein of sweet potato, and the shelf life of the active ingredient can be extended.
本考案の提供する満腹感を高め、血糖値及び血中脂肪調節機能を備えたサツマイモのタンパク質複合粒子構造は、満腹感を生じさせ、食欲を減退させ、熱量の摂取を減少させ、体重を軽減し、BMI値及び血中脂肪(トリグリセリド、コレステロール)を低下し、周辺組織を刺激して熱量を消耗する目的を達成するため、確実に満腹感を高め、血糖値及び血中脂肪の調節を行い、代謝を促進するさまざまな効果を発揮する。 The sweet potato protein composite particle structure that increases the feeling of satiety provided by the present invention and has blood glucose level and blood fat regulation functions causes a feeling of satiety, reduces appetite, reduces caloric intake, and reduces body weight And to lower the BMI value and blood fat (triglycerides, cholesterol), to stimulate the surrounding tissues and achieve the purpose of exhausting heat, to make sure to increase satiety, regulate blood sugar level and blood fat It exerts various effects of promoting metabolism.
本考案は満腹感を高め、血糖値及び血中脂肪調節機能を備えたサツマイモのタンパク質複合粒子構造を提供する。本考案の技術内容及び目的、効果を完全且つ明確に開示するために、次に詳細説明を行ない、図1には本考案の複合粒子構造の一実施例の断面図を示す。尚、本実施例は球体を選択するが、これに制限されないものとする。 The present invention provides a protein composite particle structure of sweet potato with enhanced satiety and blood glucose level and blood fat regulating functions. In order to fully and clearly disclose the technical contents, objects, and effects of the present invention, the following detailed description will be given. FIG. 1 is a cross-sectional view of an embodiment of the composite particle structure of the present invention. In addition, although a present Example selects a spherical body, it shall not be restrict | limited to this.
本考案のサツマイモのタンパク質複合粒子構造1は保護層10、有効成分層20、及びサツマイモのタンパク質を含む深部コア30を含む。そのうち、サツマイモのタンパク質を含む深部コア30は特殊技術を用いて抽出純化したサツマイモのタンパク質であり、それは天然のトリプシンインヒビター(Trypsin inhibitor)と糖タンパク質(glycoprotein)を含み、満腹感を与え、血中脂肪を低下させる効果を確実に達成する。
The sweet potato protein composite particle structure 1 of the present invention includes a
本考案は満腹感を高め、血糖値及び血中脂肪調節機能を備えたサツマイモのタンパク質複合粒子構造を提供し、そのうち、サツマイモのタンパク質複合粒子構造の粒径は120μmから500μmの範囲内とする。また、サツマイモのタンパク質を含む深部コア30の厚さは30μmから150μmの範囲内とし、有効成分層20の厚さは20μmから70μmの範囲内とする。
The present invention provides a sweet potato protein composite particle structure with enhanced satiety and blood glucose level and blood fat regulating function, wherein the particle size of the sweet potato protein composite particle structure is in the range of 120 μm to 500 μm. The thickness of the
サツマイモは、甘藷、唐芋、琉球薯とも呼ばれ、ヒルガオ科の一年生植物であり、薬膳兼用の健康食品である。サツマイモには食物繊維、βカロチン、ビタミンA、B、C、E、カリウム、鉄、銅、セレン、カルシウム等10種余りの微量元素が含まれ、栄養価が非常に高く、栄養のバランスが優れた保健食品である。 Sweet potatoes are also called sweet potatoes, tang potatoes, and Ryukyu cocoons, and are annual plants of the convolvulaceae family. Sweet potato contains dietary fiber, β-carotene, vitamins A, B, C, E, potassium, iron, copper, selenium, calcium and more than 10 kinds of trace elements, so it has a very high nutritional value and excellent nutritional balance. Health food.
本考案者は特殊な抽出技術を用いてサツマイモを精製したサツマイモのタンパク質(sweet potato protein)は、天然のトリプシンインヒビター(Trypsin inhibitor, TI)と糖タンパク質(glycoprotein)を含む。本考案のサツマイモのタンパク質は、小腸の近位端を刺激してコレシストキニン(cholecystokinin, CCK)を分泌し、それは肝臓及び中枢神経系のCCK-A受容体(CCKA)に結合し、満腹感の信号を大脳の視床下部に伝える。人体は物を食べると、すぐにCCKの放出が始まる。よって、本考案の満腹感を高め、血糖値及び血中脂肪調節機能を備えたサツマイモのタンパク質複合粒子構造を飲むと、満腹感を高め、食事量を効果的に減少させられる。また、サツマイモのタンパク質は脂肪細胞を活性化したぺルオキシーム増殖剤活性化受容体(Peroxisome Proliferators Activated Receptor, PPAR)によって血中脂肪(トリグリセリド、コレステロール)を低下させるか脂肪細胞が分泌するレプチン(Leptin)を増加して食欲を減退させ、周辺組織を刺激して熱量を消耗させる。これにより、CCKの放出に伴い、摂食量低下と熱量消耗が起き、体重をコントロールする目的を達成する。 Sweet potato protein obtained by purifying sweet potato using a special extraction technique includes natural trypsin inhibitor (TI) and glycoprotein. The sweet potato protein of the present invention stimulates the proximal end of the small intestine to secrete cholecystokinin (CCK), which binds to the CCK-A receptor (CCKA) in the liver and central nervous system, and feels full. Is transmitted to the hypothalamus of the cerebrum. The human body begins to release CCK as soon as it eats. Therefore, drinking the sweet potato protein composite particle structure with enhanced blood sugar level and blood fat regulating function according to the present invention increases the feeling of fullness and effectively reduces the amount of meal. In addition, sweet potato protein lowers blood fat (triglyceride, cholesterol) by peroxisome proliferators activated receptor (PPAR) which activated adipocytes or leptin secreted by adipocytes (Leptin) Increases appetite and decreases appetite, stimulates surrounding tissues and exhausts heat. As a result, with the release of CCK, food consumption decreases and calorie consumption occurs, achieving the purpose of controlling body weight.
本考案のサツマイモのタンパク質複合粒子構造において、そのうち、サツマイモのタンパク質を含む深部コア30のサツマイモのタンパク質は特殊な抽出精製技術を利用する。まず、サツマイモを洗浄し皮を剥き、鋸歯研磨機内で研磨してクリーム状にし、均質機に通してサツマイモ分子顆粒を微小粒子にする。サツマイモの微小粒子を氷の上に放置した後、1%から5%の酢酸(pH値は4)及び1%から10%の塩化ナトリウムから抽出したトリプシンインヒビター(Trypsin inhibitor)を加える。さらに、横型遠心分離機(回転速度1,500rpmから2,500rpm)を用いてサツマイモの微小粒子中のサツマイモの沈殿物とサツマイモ液を分離させ、サツマイモ液(必要なトリプシンインヒビター(Trypsin inhibitor)と糖タンパク質(glycoprotein)を取り出す。その後、加温バケットを用いてサツマイモ液を72℃から80℃の範囲内で加温し、トリプシンインヒビター(Trypsin inhibitor)以外の成分を除去し、アイスバケットを用いて20℃から25℃の範囲内まで温度を下げる。フィルター膜を用いてサツマイモ液中の微小粒子を除去する。また、精密ろ過膜を用いてサツマイモ液中の比較的大きな分子量の有機分子を取り除き、20から200KD分子量の目標蛋白質のサツマイモ抽出物を選択する。最後に取得したサツマイモ抽出物を真空冷凍乾燥保存でその生物活性を安定化させる。
In the sweet potato protein composite particle structure of the present invention, the sweet potato protein in the
本考案のサツマイモのタンパク質複合粒子構造は、そのうち、サツマイモのタンパク質を含む深部コア30は、オート麦繊維(Oat Cellulose)をさらに添加し、それとサツマイモのタンパク質の重量比は3:1から1:10の範囲内とし、栄養吸収を減少させる働きを助け、尚且つ満腹感を促進し、血中脂肪及びコレステロールを低下させる。
Among the protein composite particle structures of the present invention, the
本考案のサツマイモのタンパク質複合粒子構造において、有効成分層20は、ガラナ(Guarana)エキス、ダイダイ(Bitter orange)エキス、L-カルニチン(L-Carnitine)、コエンザイム(Coenzyme)Q10、フコキサンチン(Fucoxanthin)、プロバイオティクス(Probiotics)、ビタミンB6、ビタミンB2、ピコリン酸クロム(chromium picolinate)、トリプトファン(Tryptophan)、チロシン(Tyrosine)、バナバ葉(Banaba leaf)エキス、ナイアシンアミド(Niacinamide)、及びその任意の組み合わせより、少なくとも一種の成分を選択し組成するグループである。これらの有効成分層の成分は満腹感を高め、食欲を抑制し、エネルギー代謝を促進し、血糖値調節を強化し、脂肪分解を加速するのを助ける。
In the protein composite particle structure of the sweet potato of the present invention, the
満腹感の向上についてであるが、ダイダイ(Bitter orange)は柑橘類であり、ダイダイエキスはB-3アドレナリン受容体と結合する成分を含み、中枢神経の視床下部に影響を及ぼし満腹感を生じさせる他、人体の新陳代謝率を高め、脂肪細胞の分解作用を促進する。その他、トリプトファン(Tryptophan)はセロトニン(5-hydroxytryptamine, 5-HT)の前駆物質であり、文献には脳内のセロトニンが増加した時に食欲を抑制し満腹感を生じさせると記載されている。これと同時に、ビタミンB6はトリプトファン(Tryptophan)がセロトニンに転換するのを助けるため、両者には何れも満腹感を高め食欲を抑制する効果がある。 As for improving satiety, Daidai (Bitter orange) is a citrus fruit, Daidai extract contains a component that binds to the B-3 adrenergic receptor, affects the hypothalamus of the central nerve, and causes a feeling of satiety , Increase the metabolic rate of the human body and promote the degradation of fat cells. In addition, tryptophan is a precursor of serotonin (5-hydroxytryptamine, 5-HT), and the literature describes that when serotonin in the brain increases, it suppresses appetite and causes a feeling of satiety. At the same time, vitamin B6 helps Tryptophan to convert to serotonin, so both have the effect of increasing satiety and suppressing appetite.
エネルギー代謝の促進についてであるが、既に知られている通り、ミトコンドリアはエネルギー代謝の中心であり、それは電子伝達系上のタンパク質に脱共役タンパク質(Uncoupling proteins, UCP-1)を含む。フコキサンチン(Fucoxanthin)は、白色脂肪細胞のミトコンドリアの電子伝達系上の脱共役タンパク質(Uncoupling proteins, UCP-1)の増加を促進し、脂肪を分解して熱量を消耗させ、体内に蓄積された脂肪を減らす。また、L-カルニチン(L-Carnitine)は脂肪をミトコンドリア内に運び、変換されたエネルギーを身体に使用させる。コエンザイム(Coenzyme)Q10はミトコンドリア内膜で電子伝達を助け、ミトコンドリア中のエネルギー物質ATP(Adenosine Triphosphate)の産生を補助し、細胞エネルギー供給システムを迅速に動作させ、エネルギー代謝を促進する。ナイアシンアミド(Niacinamide)は還元型ニコチンアミドアデニンジヌクレオチド(Nicotinamide adenine dinucleotide, NADH)の型式でミトコンドリアの内膜で電子伝達を助け、それは細胞エネルギー供給システムを迅速に動作させ、エネルギー代謝を促進する。 As for the promotion of energy metabolism, as already known, mitochondria are the center of energy metabolism, which includes uncoupling proteins (UCP-1) in proteins on the electron transport system. Fucoxanthin promotes an increase in uncoupling proteins (UCP-1) on the mitochondrial electron transport system of white adipocytes, decomposes fat, consumes heat, and accumulates in the body Reduce fat. L-Carnitine also carries fat into mitochondria and uses the converted energy for the body. Coenzyme Q10 assists electron transfer in the inner mitochondrial membrane, assists in the production of the energy substance ATP (Adenosine Triphosphate) in the mitochondria, rapidly activates the cellular energy supply system, and promotes energy metabolism. Niacinamide, in the form of reduced nicotinamide adenine dinucleotide (NADH), aids electron transfer in the inner mitochondrial membrane, which rapidly activates the cellular energy supply system and promotes energy metabolism.
血糖値の調整についてであるが、血糖値が高くなり過ぎると脂肪に変換されて蓄積される。ピコリン酸クロム(chromium picolinate)はインシュリンに対する細胞の感度を高める。インシュリンは人体細胞のブドウ糖の利用率を促進し、人体の血糖値のバランスを保たせる。よって、ピコリン酸クロム(chromium picolinate)は糖尿病患者にとって不可欠な栄養素である。バナバ葉(Banaba leaf)エキスは適正な血糖値とインシュリンのバランスの維持を助け、血糖値の低下により引き起こされる間食の欲望を抑え、免疫システムから来るストレスを緩和する。 Regarding the adjustment of blood glucose level, if the blood glucose level becomes too high, it is converted into fat and accumulated. Chromium picolinate increases the sensitivity of cells to insulin. Insulin promotes glucose utilization in human cells and keeps the body's blood sugar level balanced. Thus, chromium picolinate is an essential nutrient for diabetics. Banaba leaf extract helps maintain the balance between proper blood sugar and insulin, reduces the desire for snacks caused by lower blood sugar, and relieves stress from the immune system.
脂肪分解については、ガラナ(Guarana)エキスは天然カフェインを含み、体内のトリグリセリドをグリセロールと脂肪酸に分解する。また、オート麦繊維(Oat Cellulose)は一部の栄養素と結合し体外に排出されるため、栄養吸収を減少させ、満腹感を促進し、血中脂肪とコレステロールを低下させる。有益菌種及び善玉菌を発酵させて生成した特殊酵素のプロバイオティクス(Probiotics)を豊富に含み、それは、脂肪、澱粉、糖分、及びタンパク質を素早く分解、代謝する作用を有し、不要な物質を除去し、肥満を抑制し、血糖値を低下させる効果を備える。 For lipolysis, Guarana extract contains natural caffeine and breaks down triglycerides in the body into glycerol and fatty acids. Oat fiber (Oat Cellulose) binds to some nutrients and is excreted from the body, reducing nutrient absorption, promoting satiety, and lowering blood fat and cholesterol. It contains abundant special enzyme probiotics produced by fermenting beneficial bacteria and good bacteria, which has the effect of rapidly decomposing and metabolizing fat, starch, sugar and protein, and is an unnecessary substance Has the effect of suppressing obesity and reducing blood sugar levels.
本考案の一つの実施例では、サツマイモのタンパク質複合粒子構造の総量を1500mgとし、それはサツマイモのタンパク質約10%以上、オート麦繊維(Oat Cellulose)約30%、L-カルニチン(L-Carnitine)2%以上、プロバイオティクス(Probiotics)6%以上、ビタミンB6 0.0006%、ビタミンB2 0.0006%、トリプトファン(Tryptophan)約10%以上、チロシン(Tyrosine)20%以上、ナイアシンアミド(Niacinamide)約0.002%を含む。
In one embodiment of the present invention, the total amount of protein complex particle structure of sweet potato is 1500 mg, which is about 10% or more of sweet potato protein, about 30% of oat fiber (Oat Cellulose), L-carnitine (L-Carnitine) 2 %, Probiotics 6% or more, Vitamin B6 0.0006%, Vitamin B2 0.0006%, Tryptophan approximately 10% or more,
本考案のもう一つの実施例では、サツマイモのタンパク質複合粒子構造の総量を1500mg以上とし、それはサツマイモのタンパク質約30%から50%、オート麦繊維(Oat Cellulose)約3%から35%、ガラナ(Guarana)エキス約3.0%、ダイダイ(Bitter orange)エキス3.0%、L-カルニチン(L-Carnitine)5%から10%、コエンザイム(Coenzyme)Q10約1.0%、フコキサンチン(Fucoxanthin)約8%から12%、プロバイオティクス(Probiotics)3%から6%、ピコリン酸クロム(chromium picolinate)約0.1%、ビタミンB6約0.133%、ビタミンB2約0.067%、トリプトファン(Tryptophan)約10%、バナバ葉(Banaba leaf)エキス約0.9%、ナイアシンアミド(Niacinamide)約0.8%を含む。 In another embodiment of the present invention, the total amount of protein composite particle structure of sweet potato is 1500 mg or more, which is about 30% to 50% sweet potato protein, about 3% to 35% oat fiber (Oat Cellulose), guarana ( Guarana extract approximately 3.0%, Daidai (Bitter orange) extract 3.0%, L-Carnitine (L-Carnitine) 5% to 10%, Coenzyme Q10 approximately 1.0%, Fucoxanthin (Fucoxanthin) approximately 8% to 12% Probiotics 3% to 6%, chromium picolinate about 0.1%, vitamin B6 about 0.133%, vitamin B2 about 0.067%, tryptophan about 10%, Banaba leaf Contains about 0.9% extract and about 0.8% niacinamide.
本考案の一つの実施例では、保護層10は人体が食用可能なゼラチン、アラビアガム、コーンシュガーガム、トラガカントガム等の膠質物質から選択する。本考案のもう一つの実施例では、保護層10には賦形剤をさらに含み、該賦形剤は調味料、甘味料、防腐剤、抗酸化剤、キレート剤、浸透剤、潤滑剤、着色剤、結合剤より選択し組成したグループである。
In one embodiment of the present invention, the
本考案のもう一つの実施例では、保護層10はフィルムコーティング(film coating)を用いて加工したフィルムコーティング保護層である。該フィルムコーティング保護層は、糖衣、継続的放出型フィルムコーティング、腸溶性フィルムコーティング、透明水溶性フィルムコーティング、黄色フィルムコーティング等の何れか一種或いは多種の組み合わせによって組成される。本考案のサツマイモのタンパク質複合粒子構造に基づき、口から服用する錠剤のフィルムコーティングは水に接触しても尚、表面の滑らかさを保ち続け、使用者が飲み込んだ時に口内や食道に粘着するのを防ぎ、胃腸に対する刺激を減少させる。
In another embodiment of the present invention, the
前記実施例に基づき、保護層10が透明水溶性フィルムコーティングである場合、それには、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ヒドロキシエチルセルロース、メチルヒドロキシエチルセルロース等のセルロースポリマーと、ポリビニルアセタールジエチルアミノアセテート、アミノアルキルメタクリレートコポリマーE、ポリビニルピロリドン等の合成ポリマーと、トリグルコシド(triglucoside)等の多糖とを含む。
Based on the above embodiment, when the
本考案の好ましい実施例では、保護層10は腸溶性フィルムコーティングであり、該腸溶性フィルムコーティングは腸管の環境内に至って初めて溶解する。並びに、サツマイモ抽出物の活性成分を放出することにより、活性成分は胃酸による分解、破壊を免れる。該腸溶性フィルムコーティングの組成は、ひまし油、シェラック、ミネラルオイル、プロピレングリコール、ポリメタクリル酸メチル樹脂、クエン酸トリエチル、クエン酸トリブチル、フタル酸ジヘキシル、ポリエチレングリコール、フタル酸酢酸セルロース、ヒドロキシプロピルフタル酸メチルセルロース、ヒドロキシプロピルメチルセルロースコハク酸酢酸塩などの何れか一つ、或いは多種の組み合わせにより組成される。
In a preferred embodiment of the present invention, the
よって、本考案の提供する満腹感を高め、血糖値及び血中脂肪調節機能を備えたサツマイモのタンパク質複合粒子構造は、保護層10によってサツマイモのタンパク質を含む深部コア30と有効成分層20の活性成分を完全に包覆し、並びに、外界汚染による変質を防ぐことができ、同時に、サツマイモのタンパク質の活性成分の有効期限を延長し保持する効果を備える。さらに、保護層10によりサツマイモのタンパク質の活性成分が胃の消化液によって破壊されずに、迅速吸収を助ける効果を備える。
Therefore, the protein composite particle structure of sweet potato with enhanced satiety provided by the present invention and having blood glucose level and blood fat regulating function is the activity of the
本考案の一つの好ましい実施例では、サツマイモのタンパク質複合粒子構造はカプセルに充填する形態としてもよい。図2に示すとおり、カプセル40は食用レベルの膠質原料により製作し、カプセル40はそれぞれ内側に窪む形態の凹溝50を形成し、尚且つカプセル40は凹溝50の開口で相互に蓋をして連結する。本考案のサツマイモのタンパク質複合粒子構造1はカプセル40内に充填可能である。
In one preferred embodiment of the present invention, the protein composite particle structure of sweet potato may be filled in a capsule. As shown in FIG. 2, the
本考案の一つの好ましい実施例では、サツマイモのタンパク質複合粒子構造1は室温下の純水中に溶かし、均等に溶液に分散させた後飲用するか、直接口内に投入する。図3に示すとおり、サツマイモのタンパク質複合粒子構造1を袋詰めパック60として製作してもよい。使用者は切口70を切り開くと本考案のサツマイモのタンパク質複合粒子構造1を直接服用できる。それは保護層10、有効成分層20、サツマイモのタンパク質を含む深部コア30を含み、便利に随時使用できる。
In one preferred embodiment of the present invention, the sweet potato protein composite particle structure 1 is dissolved in pure water at room temperature and dispersed evenly in the solution before drinking or directly into the mouth. As shown in FIG. 3, the protein composite particle structure 1 of sweet potato may be manufactured as a
本考案の一つの好ましい実施例では、乳糖、澱粉、セルロース、クエン酸あるいはリンゴ酸、炭酸水素ナトリウムの発砲成分または放出制御成分等の錠剤ベースを添加してもよく、加圧方式で、例えば二層錠、発砲錠、放出制御錠等を打錠する。図4に示すとおり、複数のサツマイモのタンパク質複合粒子構造1を錠剤ベース80に均等に散布させて錠剤90を製作し、該錠剤は保健用食品或いは医薬品とする。
In one preferred embodiment of the invention, a tablet base such as lactose, starch, cellulose, citric acid or malic acid, sodium bicarbonate foaming control component or controlled release component may be added, Tablets layered tablets, foamed tablets, controlled release tablets, etc. As shown in FIG. 4, a plurality of sweet potato protein composite particle structures 1 are evenly sprayed on a
本考案の一つの好ましい実施例では、被験者は毎朝一回空腹時に図2に示した袋詰めパック60を服用し、30分後に食事を始める。45日から60日続けて服用した後、被験者の体重、食事摂取量、腹部の脂肪、及びコレステロールの各方面に明らかな改善がみられた。
In one preferred embodiment of the invention, the subject takes the
前述したとおり、本考案のサツマイモのタンパク質複合粒子構造は、特殊技術を用いてサツマイモ内から天然のサツマイモのタンパク質を抽出、精製する。それには天然のトリプシンインヒビター(Trypsin inhibitor, TI)と糖タンパク質(glycoprotein)を含み、満腹感を高め、効果的に食事摂取量を減少させる。並びに、その他成分を備える本考案のサツマイモのタンパク質複合粒子構造は、満腹感を生じさせ、食欲を低下し、熱量の摂取を減少し、体重を減量し、BMI値及び血中脂肪(トリグリセリド、コレステロール)を低下し、周辺組織を刺激して熱量を消耗する目的を達成する。また、本考案のサツマイモのタンパク質複合粒子構造を水中に溶解すると、迅速に水中に溶け込み、飲用後は、サツマイモ中の天然のトリプシンインヒビターと糖タンパク質成分が直接人体によって吸収されるため、吸収効果を効果的に高めることができる。また、サツマイモのタンパク質複合粒子構造はダイエット中の飢餓感を効果的に減少し、食事摂取量を減少させ、吸収を阻止し、熱量の消耗を高めるため、最も好ましいダイエット効果を発揮する。同時に、本考案の多種形態によって消費者の利便性と選択性を向上させられるため、身体の健康に役立つ機能性サプリメントでもある。 As described above, the protein composite particle structure of the sweet potato of the present invention extracts and purifies natural sweet potato proteins from the sweet potato using a special technique. It contains natural trypsin inhibitor (TI) and glycoprotein, which increases satiety and effectively reduces food intake. In addition, the protein composite particle structure of the sweet potato of the present invention comprising other components causes a feeling of satiety, reduces appetite, reduces calorie intake, loses weight, BMI value and blood fat (triglyceride, cholesterol ) To achieve the purpose of stimulating the surrounding tissues and exhausting heat. In addition, when the protein composite particle structure of the sweet potato of the present invention is dissolved in water, it quickly dissolves in water, and after drinking, the natural trypsin inhibitor and glycoprotein components in the sweet potato are directly absorbed by the human body. Can be effectively increased. In addition, the protein composite particle structure of sweet potato effectively reduces the feeling of starvation during dieting, reduces food intake, prevents absorption, and increases heat consumption. At the same time, the various forms of the present invention can improve convenience and selectivity for consumers, so that it is also a functional supplement useful for physical health.
1 サツマイモのタンパク質複合粒子構造
10 保護層
20 有効成分層
30 深部コア
40 カプセル
50 凹溝
60 袋詰めパック
70 切口
80 錠剤ベース
90 錠剤
DESCRIPTION OF SYMBOLS 1 Sweet potato protein
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013003766U JP3185984U (en) | 2013-07-02 | 2013-07-02 | Sweet potato protein composite particle structure with enhanced satiety, blood glucose level and blood fat regulation function |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013003766U JP3185984U (en) | 2013-07-02 | 2013-07-02 | Sweet potato protein composite particle structure with enhanced satiety, blood glucose level and blood fat regulation function |
Publications (1)
Publication Number | Publication Date |
---|---|
JP3185984U true JP3185984U (en) | 2013-09-12 |
Family
ID=50429693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013003766U Expired - Fee Related JP3185984U (en) | 2013-07-02 | 2013-07-02 | Sweet potato protein composite particle structure with enhanced satiety, blood glucose level and blood fat regulation function |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3185984U (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190086875A (en) * | 2018-01-15 | 2019-07-24 | 한국식품연구원 | Composition comprising as an active ingredient a sweet potato extract |
-
2013
- 2013-07-02 JP JP2013003766U patent/JP3185984U/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190086875A (en) * | 2018-01-15 | 2019-07-24 | 한국식품연구원 | Composition comprising as an active ingredient a sweet potato extract |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9056049B2 (en) | Micro-particle comprising a protein extract from sweet potato for extending satiety and controlling blood glucose and lipid levels | |
CN104855956A (en) | Medical formula food for insomnia | |
CN104856003A (en) | Non-full nutritional formula food for patients with diabetes | |
CN103417837B (en) | Medlar health preserving cream of a kind of medicine-food two-purpose and preparation method thereof | |
CN104855967A (en) | Non-whole nutrient formula food for patients having obesity or fat-reducing surgery | |
CN104839664A (en) | Medical formula food for osteoporosis | |
CN102224891A (en) | Sugar alcohol honey apple jam and preparation method thereof | |
CN104855985A (en) | Non-complete-nutrition formula food for high uric acid | |
CN105410896A (en) | Hepatogenic diabetes full nutritional formula food | |
CN104286273A (en) | Application of dendrobium candidum and tea leaf product thereof | |
CN104855994A (en) | Non-full nutritional formula food for patients with nephropathy | |
CN104855975A (en) | Non-total-nutrient formula food for sarcopenia syndrome | |
CN104855997A (en) | Non-whole nutrient formula food for osteoporosis | |
CN102551139A (en) | Weight-losing dense mix made of red jujube and astragalus mongholicus | |
CN104187613A (en) | Total-nutrient formulated food for patients with insomnia | |
CN104856000A (en) | Non-complete-nutrition formula food for insomnia | |
CN104839698A (en) | Cardiovascular disease non-total nutrient formula food | |
CN104855970A (en) | Non-whole nutrient formula food for hypertension | |
CN102511876B (en) | Hawthorn red jujube thick syrup and production process thereof | |
JP3185984U (en) | Sweet potato protein composite particle structure with enhanced satiety, blood glucose level and blood fat regulation function | |
CN103621871B (en) | Compound amino acid health-care product and preparation method thereof | |
CN105166653A (en) | Stomach-invigorating and health-preserving sweet potato gruel and preparing method thereof | |
CN109452417A (en) | A kind of pure natural fat eliminating Weight reducing tea drink and preparation method thereof | |
CN104855969A (en) | Non-whole nutrient formula food for liver diseases | |
CN102885364A (en) | Corn beverage and its preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R150 | Certificate of patent or registration of utility model |
Ref document number: 3185984 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R323113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R323113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
LAPS | Cancellation because of no payment of annual fees |